RT Journal Article SR Electronic T1 Machine learning suggests polygenic contribution to cognitive dysfunction in amyotrophic lateral sclerosis JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2019.12.23.19014407 DO 10.1101/2019.12.23.19014407 A1 Katerina Placek A1 Michael Benatar A1 Joanne Wuu A1 Evadnie Rampersaud A1 Laura Hennessy A1 Vivianna M. Van Deerlin A1 Murray Grossman A1 David J. Irwin A1 Lauren Elman A1 Leo McCluskey A1 Colin Quinn A1 Volkan Granit A1 Jeffrey M. Statland A1 Ted M. Burns A1 John Ravits A1 Andrea Swenson A1 Jon Katz A1 Erik Pioro A1 Carlayne Jackson A1 James Caress A1 Yuen So A1 Samuel Maiser A1 David Walk A1 Edward B. Lee A1 John Q. Trojanowski A1 Philip Cook A1 James Gee A1 Jin Sha A1 Adam C. Naj A1 Rosa Rademakers A1 The CReATe Consortium A1 Wenan Chen A1 Gang Wu A1 J. Paul Taylor A1 Corey T. McMillan YR 2020 UL http://medrxiv.org/content/early/2020/09/16/2019.12.23.19014407.abstract AB Amyotrophic lateral sclerosis (ALS) is a multi-system disease characterized primarily by progressive muscle weakness. Cognitive dysfunction is commonly observed in patients, however factors influencing risk for cognitive dysfunction remain elusive. Using sparse canonical correlation analysis (sCCA), an unsupervised machine-learning technique, we observed that single nucleotide polymorphisms collectively associate with baseline cognitive performance in a large ALS patient cohort (N=327) from the multicenter Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium. We demonstrate that a polygenic risk score derived using sCCA relates to longitudinal cognitive decline in the same cohort, and also to in vivo cortical thinning in the orbital frontal cortex, anterior cingulate cortex, lateral temporal cortex, premotor cortex, and hippocampus (N=90) as well as post mortem motor cortical neuronal loss (N=87) in independent ALS cohorts from the University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Our findings suggest that common genetic polymorphisms may exert a polygenic contribution to the risk of cortical disease vulnerability and cognitive dysfunction in ALS.Competing Interest StatementThe following authors declare the following competing interests: C.T.M. receives financial support from Biogen and has provided consulting for Axon Advisors. M.B. reports grants from National Institutes of Health, the ALS Association, the Muscular Dystrophy Association, the Centers for Disease Control and Prevention, the Department of Defense, and Target ALS during the conduct of the study; personal fees from Mitsubishi Tanabe Pharma, AveXis, Prilenia, Genentech, and Roche outside the submitted work. In addition, M.B. has a provisional patent entitled "Determining Onset of Amyotrophic Lateral Sclerosis," and serves as a site investigator on clinical trials funded by Biogen and Orphazyme. All other authors declare no competing interests. Clinical TrialNCT02327845Clinical Protocols https://projectreporter.nih.gov/reporter_searchresults.cfm Funding StatementThe CReATe Consortium (U54NS092091) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR). Additional research support was provided by the National Institutes of Health (NS106754, AG017586, NS092091, AG054060). The genomics sequencing was funded by St. Jude Childrens Research Hospital American Lebanese Syrian Associated Charities (ALSAC) with additional support from the ALS Association for biorepository and sequencing costs (grants 17-LGCA-331 and 16-TACL-242).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll R software code generated to perform the reported analyses has been deposited online (https://github.com/pennbindlab/PolygenicALSCognitive). Please review the associated README file for details of data access. Briefly, associated datasets can be obtained as follows: The Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium Phenotype-Genotype Biomarker (PGB) Study data will be deposited at the NIH-supported Data Management and Coordinating Center (DMCC) and the Database of Genotypes and Phenotypes (dbGaP) using procedures outlined by the Rare Disease Clinical Research Network (RDCRN) of the National Institutes of Health (NIH). As detailed in the patient consent process, only researchers with an approved study may be able to see and use patient information and only de-identified data, which does not include anything that might directly identify patients, will be shared with study investigators and approved investigators from the general scientific community for research purposes. If you would like to access this data, please contact the CReATe Consortium at ProjectCReATe@miami.edu for a data request form. De-identified raw T1-weighted MRI and voxelwise cortical thickness images will be made available to researchers through an approved request pending review by the Penn Neurodegenerative Data Sharing Committee. To request access please complete the following online data request form: https://www.pennbindlab.com/data-sharing. Neuropathological data and associated data fields have been deposited along with all associated statistical code in an online repository (https://github.com/pennbindlab/PolygenicALSCognitive). https://github.com/pennbindlab/PolygenicALSCognitive